Mahiro Iizuka-Ohashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahiro Iizuka-Ohashi has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Motoki Watanabe
Department of Molecular-Targeting Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan
3 shared publications - Mamiko Sukeno
Drug Discovery Center, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
2 shared publications - Toshiyuki Sakai
Department of Drug Discovery Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
2 shared publications - Akira Watanabe
Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
1 shared publication Chikage Kato
Division of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine
1 shared publication- Chikage Kato
Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
1 shared publication
Latest Publications
- 20 May 2026
- Published by Springer Nature in Breast Cancer
- Vol. 33 (4) , 841-852
Comparative evaluation of treatment recommendations generated by generative AI and breast cancer specialists for advanced and recurrent breast cancer: a multidimensional assessment of evidence interpretation and clinical decision support
Background Large language models (LLMs), a form of generative artificial intelligence (AI), are increasingly explored for clinical applications due to their ability to synthesize medical information. In breast cancer care, where therapeutic decision-making is complex because of expanding treatment options, AI-based decision support tools may improve efficiency and consistency. However, their clinical validity and safety remain insufficiently evaluated in real-world settings. The present study aimed to compare the characteristics of treatment recommendations generated by a large language model with those proposed by breast cancer specialists using identical clinical information. Methods This retrospective observational study included 100 patients with advanced or recurrent breast cancer. Clinical information was provided to ChatGPT using a standardized prompt to generate treatment recommendations. Six board-certified breast cancer specialists independently proposed treatment strategies for the same cases. Recommendations were evaluated using five predefined criteria: 1. Comprehensiveness and appropriateness of literature selection, 2. Accuracy of interpretation of key evidence, 3. Clinical appropriateness and diversity of treatment options, 4. Accuracy of adverse event information, 5. Time required to generate recommendations. Group comparisons were performed using linear mixed-effects models with case and evaluator as random effects. Results ChatGPT achieved higher scores than specialists across all five evaluation criteria, with the largest difference observed for accuracy of key evidence interpretation. The mean total score was 93.7 for ChatGPT and 44.1 for specialists, and linear mixed-effects model analysis confirmed a significantly higher total score for ChatGPT (p < 0.001). These findings suggest that AI-generated responses tended to provide more comprehensive and structured summaries of available evidence within the predefined evaluation framework. Conclusions LLMs were able to generate comprehensive and structured treatment recommendations based on the provided clinical information. However, these findings primarily reflect differences in information synthesis under predefined evaluation criteria rather than superiority in real-world clinical decision-making. Given the potential risk of hallucinations, AI should be positioned as an assistive tool to support specialist-led decision-making in breast cancer care.
- 20 May 2026
- Published by Springer Nature in Breast Cancer
- Vol. 33 (4) , 841-852
Comparative evaluation of treatment recommendations generated by generative AI and breast cancer specialists for advanced and recurrent breast cancer: a multidimensional assessment of evidence interpretation and clinical decision support
Background Large language models (LLMs), a form of generative artificial intelligence (AI), are increasingly explored for clinical applications due to their ability to synthesize medical information. In breast cancer care, where therapeutic decision-making is complex because of expanding treatment options, AI-based decision support tools may improve efficiency and consistency. However, their clinical validity and safety remain insufficiently evaluated in real-world settings. The present study aimed to compare the characteristics of treatment recommendations generated by a large language model with those proposed by breast cancer specialists using identical clinical information. Methods This retrospective observational study included 100 patients with advanced or recurrent breast cancer. Clinical information was provided to ChatGPT using a standardized prompt to generate treatment recommendations. Six board-certified breast cancer specialists independently proposed treatment strategies for the same cases. Recommendations were evaluated using five predefined criteria: 1. Comprehensiveness and appropriateness of literature selection, 2. Accuracy of interpretation of key evidence, 3. Clinical appropriateness and diversity of treatment options, 4. Accuracy of adverse event information, 5. Time required to generate recommendations. Group comparisons were performed using linear mixed-effects models with case and evaluator as random effects. Results ChatGPT achieved higher scores than specialists across all five evaluation criteria, with the largest difference observed for accuracy of key evidence interpretation. The mean total score was 93.7 for ChatGPT and 44.1 for specialists, and linear mixed-effects model analysis confirmed a significantly higher total score for ChatGPT (p < 0.001). These findings suggest that AI-generated responses tended to provide more comprehensive and structured summaries of available evidence within the predefined evaluation framework. Conclusions LLMs were able to generate comprehensive and structured treatment recommendations based on the provided clinical information. However, these findings primarily reflect differences in information synthesis under predefined evaluation criteria rather than superiority in real-world clinical decision-making. Given the potential risk of hallucinations, AI should be positioned as an assistive tool to support specialist-led decision-making in breast cancer care.
- Open Access
- 1 May 2021
- Published by The Society for Free Radical Research Japan in Journal of Clinical Biochemistry and Nutrition
- Vol. 68 (3) , 235-242
Oxidative stress induces EGFR inhibition-related skin cell death
Cutaneous side effects are often observed in patients treated with chemotherapeutic agents, including those treated with epidermal growth factor receptor (EGFR) inhibitors. These side effects are not fatal but often require dose reduction of chemotherapies. The mechanisms of epidermal growth factor receptor inhibition-related dermatologic toxicities are unclear, and prophylactic approaches are not well-established. To explore the mechanisms of the cutaneous side effects induced by epidermal growth factor receptor inhibition, we analyzed the metabolome using human keratinocyte cells. We first demonstrated that afatinib and lapatinib induced apoptosis in HaCaT cells. Using liquid chromatography-mass spectrometry, we detected 676 and 482 metabolites and compounds in the cells and media, respectively. We observed diverse metabolic alterations, including glycolysis, TCA metabolism, and polyamine metabolism, and also found a change in glutathione metabolites after epidermal growth factor receptor inhibition, which led to the accumulation of reactive oxygen species. Supplementation of N-acetyl cysteine partly rescued the afatinib-induced apoptosis, suggesting that reactive oxygen species are involved in the cytotoxicity of skin cells. We observed epidermal growth factor receptor inhibitor-associated comprehensive metabolic changes in human keratinocyte cells, suggesting that oxidative stress evokes cutaneous side effects induced by EGFR inhibition.
- 1 May 2021
- Published by The Society for Free Radical Research Japan in Journal of Clinical Biochemistry and Nutrition
- Vol. 68 (3) , 235-242
Open AccessOxidative stress induces EGFR inhibition-related skin cell death
Cutaneous side effects are often observed in patients treated with chemotherapeutic agents, including those treated with epidermal growth factor receptor (EGFR) inhibitors. These side effects are not fatal but often require dose reduction of chemotherapies. The mechanisms of epidermal growth factor receptor inhibition-related dermatologic toxicities are unclear, and prophylactic approaches are not well-established. To explore the mechanisms of the cutaneous side effects induced by epidermal growth factor receptor inhibition, we analyzed the metabolome using human keratinocyte cells. We first demonstrated that afatinib and lapatinib induced apoptosis in HaCaT cells. Using liquid chromatography-mass spectrometry, we detected 676 and 482 metabolites and compounds in the cells and media, respectively. We observed diverse metabolic alterations, including glycolysis, TCA metabolism, and polyamine metabolism, and also found a change in glutathione metabolites after epidermal growth factor receptor inhibition, which led to the accumulation of reactive oxygen species. Supplementation of N-acetyl cysteine partly rescued the afatinib-induced apoptosis, suggesting that reactive oxygen species are involved in the cytotoxicity of skin cells. We observed epidermal growth factor receptor inhibitor-associated comprehensive metabolic changes in human keratinocyte cells, suggesting that oxidative stress evokes cutaneous side effects induced by EGFR inhibition.
- Open Access
Rabdosianone I, a Bitter Diterpene from an Oriental Herb, Suppresses Thymidylate Synthase Expression by Directly Binding to ANT2 and PHB2
Natural products have numerous bioactivities and are expected to be a resource for potent drugs. However, their direct targets in cells often remain unclear. We found that rabdosianone I, which is a bitter diterpene from an oriental herb for longevity, Isodon japonicus Hara, markedly inhibited the growth of human colorectal cancer cells by downregulating the expression of thymidylate synthase (TS). Next, using rabdosianone I-immobilized nano-magnetic beads, we identified two mitochondrial inner membrane proteins, adenine nucleotide translocase 2 (ANT2) and prohibitin 2 (PHB2), as direct targets of rabdosianone I. Consistent with the action of rabdosianone I, the depletion of ANT2 or PHB2 reduced TS expression in a different manner. The knockdown of ANT2 or PHB2 promoted proteasomal degradation of TS protein, whereas that of not ANT2 but PHB2 reduced TS mRNA levels. Thus, our study reveals the ANT2- and PHB2-mediated pleiotropic regulation of TS expression and demonstrates the possibility of rabdosianone I as a lead compound of TS suppressor.
Open AccessRabdosianone I, a Bitter Diterpene from an Oriental Herb, Suppresses Thymidylate Synthase Expression by Directly Binding to ANT2 and PHB2
Natural products have numerous bioactivities and are expected to be a resource for potent drugs. However, their direct targets in cells often remain unclear. We found that rabdosianone I, which is a bitter diterpene from an oriental herb for longevity, Isodon japonicus Hara, markedly inhibited the growth of human colorectal cancer cells by downregulating the expression of thymidylate synthase (TS). Next, using rabdosianone I-immobilized nano-magnetic beads, we identified two mitochondrial inner membrane proteins, adenine nucleotide translocase 2 (ANT2) and prohibitin 2 (PHB2), as direct targets of rabdosianone I. Consistent with the action of rabdosianone I, the depletion of ANT2 or PHB2 reduced TS expression in a different manner. The knockdown of ANT2 or PHB2 promoted proteasomal degradation of TS protein, whereas that of not ANT2 but PHB2 reduced TS mRNA levels. Thus, our study reveals the ANT2- and PHB2-mediated pleiotropic regulation of TS expression and demonstrates the possibility of rabdosianone I as a lead compound of TS suppressor.
- Open Access
Deactivation of Glutaminolysis Sensitizes PIK3CA-Mutated Colorectal Cancer Cells to Aspirin-Induced Growth Inhibition
Aspirin is one of the most promising over-the-counter drugs to repurpose for cancer treatment. In particular, aspirin has been reported to be effective against PIK3CA-mutated colorectal cancer (CRC); however, little information is available on how the PIK3CA gene status affects its efficacy. We found that the growth inhibitory effects of aspirin were impaired upon glutamine deprivation in PIK3CA-mutated CRC cells. Notably, glutamine dependency of aspirin-mediated growth inhibition was observed in PIK3CA-mutated cells but not PIK3CA wild type cells. Mechanistically, aspirin induced G1 arrest in PIK3CA-mutated CRC cells and inhibited the mTOR pathway, inducing the same phenotypes as glutamine deprivation. Moreover, our study including bioinformatic approaches revealed that aspirin increased the expression levels of glutaminolysis-related genes with upregulation of activating transcription factor 4 (ATF4) in PIK3CA-mutated CRC cells. Lastly, the agents targeting glutaminolysis demonstrated significant combined effects with aspirin on PIK3CA-mutated CRC cells. Thus, these findings not only suggest the correlation among aspirin efficacy, PIK3CA mutation and glutamine metabolism, but also the rational combinatorial treatments of aspirin with glutaminolysis-targeting agents against PIK3CA-mutated CRC.
Open AccessDeactivation of Glutaminolysis Sensitizes PIK3CA-Mutated Colorectal Cancer Cells to Aspirin-Induced Growth Inhibition
Aspirin is one of the most promising over-the-counter drugs to repurpose for cancer treatment. In particular, aspirin has been reported to be effective against PIK3CA-mutated colorectal cancer (CRC); however, little information is available on how the PIK3CA gene status affects its efficacy. We found that the growth inhibitory effects of aspirin were impaired upon glutamine deprivation in PIK3CA-mutated CRC cells. Notably, glutamine dependency of aspirin-mediated growth inhibition was observed in PIK3CA-mutated cells but not PIK3CA wild type cells. Mechanistically, aspirin induced G1 arrest in PIK3CA-mutated CRC cells and inhibited the mTOR pathway, inducing the same phenotypes as glutamine deprivation. Moreover, our study including bioinformatic approaches revealed that aspirin increased the expression levels of glutaminolysis-related genes with upregulation of activating transcription factor 4 (ATF4) in PIK3CA-mutated CRC cells. Lastly, the agents targeting glutaminolysis demonstrated significant combined effects with aspirin on PIK3CA-mutated CRC cells. Thus, these findings not only suggest the correlation among aspirin efficacy, PIK3CA mutation and glutamine metabolism, but also the rational combinatorial treatments of aspirin with glutaminolysis-targeting agents against PIK3CA-mutated CRC.